View ValuationCompumedics 향후 성장Future 기준 점검 5/6Compumedics (는) 각각 연간 43.5% 및 19.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 43.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 40.3% 로 예상됩니다.핵심 정보43.5%이익 성장률43.58%EPS 성장률Medical Equipment 이익 성장13.4%매출 성장률19.4%향후 자기자본이익률40.32%애널리스트 커버리지Low마지막 업데이트17 Apr 2026최근 향후 성장 업데이트공시 • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.공시 • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.공시 • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.공시 • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.모든 업데이트 보기Recent updates공시 • Jun 09Compumedics Limited Announces Appointment of Mike Stone as Chief Commercial Officer for Its US OperationsCompumedics Limited announced appointment of Mike Stone as Chief Commercial Officer for its US operations. Mike brings over 20 years of medical device commercial leadership, with a proven record of scaling sales organizations, retaining key talent through M&A transitions, and integrating acquired businesses. Since joining, he has already strengthened the U.S. team with several high-caliber hires, with additional key appointments underway. Mike is charged with two strategic priorities: building out Compumedics' US neurodiagnostics business and strengthening the sleep and IDTF commercial teams to support continued growth, including Somfit, the company's EEG-enabled home sleep testing platform. Mike joins from Baxter International, where he led commercial operations spanning alternate site distribution and pharmaceutical manufacturing channels. Prior to Baxter, he served as Vice President of Sales at Smiths Medical, managing a $500 million plus P&L and holding the commercial organization together through its acquisition by ICU Medical. Earlier in his career, Mike led post-acquisition integration and team building across multiple transactions at Henry Schein, the Fortune 250 healthcare products and distribution leader. His tenure as Vice President of Sales for Neurology at Nihon Kohden gives him direct domain experience in EEG, sleep diagnostics, and software sales, where he transformed an underperforming business and drove strong double-digit growth sustained over multiple years. Mike holds an MBA from Georgia State University and a BS from the University of South Florida. He is based in Wellington, Florida.Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Chris Barrys was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Chris Barys was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Oct 30Compumedics Limited Elects Mr. Christopher Barys as DirectorCompumedics Limited elected Mr. Christopher Barys as director.공시 • Oct 15Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,543,860 Price\Range: AUD 0.285 Discount Per Security: AUD 0.0171 Transaction Features: Subsequent Direct Listing공시 • Oct 01Compumedics Limited, Annual General Meeting, Oct 30, 2025Compumedics Limited, Annual General Meeting, Oct 30, 2025. Location: 30-40 flockhart street, abbotsford victoria 3067, and via zoom meeting, AustraliaReported Earnings • Aug 28Full year 2025 earnings released: AU$0.007 loss per share (vs AU$0.002 loss in FY 2024)Full year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 276% from FY 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Dec 05Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,269,231 Price\Range: AUD 0.26 Discount Per Security: AUD 0.0156 Transaction Features: Subsequent Direct ListingReported Earnings • Oct 02Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.002 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.3m (up 17% from FY 2023). Net loss: AU$338.0k (loss narrowed 95% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.2m (up 17% from FY 2023). Net loss: AU$499.0k (loss narrowed 92% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (AU$65.3m market cap, or US$44.1m).Board Change • Dec 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 02Full year 2023 earnings released: AU$0.035 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.035 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 11% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.공시 • Sep 28Compumedics Limited, Annual General Meeting, Oct 31, 2023Compumedics Limited, Annual General Meeting, Oct 31, 2023, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street, Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the Company and the reports of the Directors and the Company's auditor for the year ended 30 June 2023; to consider the election of Director; and to consider the adoption of Remuneration Report.New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 43% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (AU$35.4m market cap, or US$23.0m).공시 • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.공시 • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.Reported Earnings • Mar 03First half 2023 earnings released: AU$0.041 loss per share (vs AU$0.002 profit in 1H 2022)First half 2023 results: AU$0.041 loss per share (down from AU$0.002 profit in 1H 2022). Revenue: AU$19.2m (up 14% from 1H 2022). Net loss: AU$7.21m (down AU$7.50m from profit in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.공시 • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.Board Change • Jan 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.Board Change • Aug 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jul 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Mar 03First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: EPS: AU$0.002 (down from AU$0.007 in 1H 2021). Revenue: AU$16.8m (down 7.0% from 1H 2021). Net income: AU$287.0k (down 78% from 1H 2021). Profit margin: 1.7% (down from 7.3% in 1H 2021). Revenue missed analyst estimates by 4.4%. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Board Change • Jan 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Tucson Dunn was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 31Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Non-Executive Director Tucson Dunn was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 01Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$35.7m (up 1.9% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.8% (up from net loss in FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 28Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$37.3m (up 6.2% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.7% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Mar 10New 90-day low: AU$0.41The company is down 17% from its price of AU$0.49 on 08 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period.Is New 90 Day High Low • Jan 13New 90-day low: AU$0.41The company is down 7.0% from its price of AU$0.45 on 16 October 2020. The Australian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$1.73 per share.이익 및 매출 성장 예측CHIA:CMP - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202911617101216/30/2028951381016/30/20278095816/30/202666424112/31/2025580-14N/A9/30/202555-1-42N/A6/30/202551-1-70N/A3/31/202549-1-70N/A12/31/202447-2-7-1N/A9/30/202449-1-40N/A6/30/2024500-12N/A3/31/2024500-12N/A12/31/2023501-12N/A9/30/202347-2-31N/A6/30/202343-6-40N/A3/31/202342-6-31N/A12/31/202241-6-22N/A9/30/202240-2-12N/A6/30/202239103N/A3/31/202237103N/A12/31/202134002N/A9/30/202135002N/A6/30/202136101N/A3/31/202135-212N/A12/31/202035-524N/A9/30/202035-514N/A6/30/202035-615N/A3/31/202038-105N/A12/31/2019413-15N/A9/30/2019414N/A5N/A6/30/2019424N/A5N/A3/31/2019413N/A4N/A12/31/2018403N/A3N/A9/30/2018383N/A2N/A6/30/2018373N/A1N/A3/31/2018362N/A0N/A12/31/2017342N/A-1N/A9/30/2017342N/A0N/A6/30/2017341N/A1N/A3/31/2017351N/A2N/A12/31/2016362N/A4N/A9/30/2016372N/A3N/A6/30/2016383N/A2N/A3/31/2016363N/A2N/A12/31/2015353N/A1N/A9/30/2015342N/A2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CMP 의 연간 예상 수익 증가율(43.5%)이 saving rate(3.6%)보다 높습니다.수익 vs 시장: CMP 의 연간 수익(43.5%)이 Australian 시장(11.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: CMP 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: CMP 의 수익(연간 19.4%)이 Australian 시장(연간 5.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: CMP 의 수익(연간 19.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CMP의 자본 수익률은 3년 후 40.3%로 매우 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/09 09:49종가2026/07/09 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Compumedics Limited는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ian MartinNew Street Research LLPPaul JenszPAC Partners Securities Pty. Ltd.Stephen ScottTaylor Collison Limited
공시 • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.
공시 • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.
공시 • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.
공시 • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.
공시 • Jun 09Compumedics Limited Announces Appointment of Mike Stone as Chief Commercial Officer for Its US OperationsCompumedics Limited announced appointment of Mike Stone as Chief Commercial Officer for its US operations. Mike brings over 20 years of medical device commercial leadership, with a proven record of scaling sales organizations, retaining key talent through M&A transitions, and integrating acquired businesses. Since joining, he has already strengthened the U.S. team with several high-caliber hires, with additional key appointments underway. Mike is charged with two strategic priorities: building out Compumedics' US neurodiagnostics business and strengthening the sleep and IDTF commercial teams to support continued growth, including Somfit, the company's EEG-enabled home sleep testing platform. Mike joins from Baxter International, where he led commercial operations spanning alternate site distribution and pharmaceutical manufacturing channels. Prior to Baxter, he served as Vice President of Sales at Smiths Medical, managing a $500 million plus P&L and holding the commercial organization together through its acquisition by ICU Medical. Earlier in his career, Mike led post-acquisition integration and team building across multiple transactions at Henry Schein, the Fortune 250 healthcare products and distribution leader. His tenure as Vice President of Sales for Neurology at Nihon Kohden gives him direct domain experience in EEG, sleep diagnostics, and software sales, where he transformed an underperforming business and drove strong double-digit growth sustained over multiple years. Mike holds an MBA from Georgia State University and a BS from the University of South Florida. He is based in Wellington, Florida.
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Chris Barrys was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.
Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Chris Barys was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Oct 30Compumedics Limited Elects Mr. Christopher Barys as DirectorCompumedics Limited elected Mr. Christopher Barys as director.
공시 • Oct 15Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,543,860 Price\Range: AUD 0.285 Discount Per Security: AUD 0.0171 Transaction Features: Subsequent Direct Listing
공시 • Oct 01Compumedics Limited, Annual General Meeting, Oct 30, 2025Compumedics Limited, Annual General Meeting, Oct 30, 2025. Location: 30-40 flockhart street, abbotsford victoria 3067, and via zoom meeting, Australia
Reported Earnings • Aug 28Full year 2025 earnings released: AU$0.007 loss per share (vs AU$0.002 loss in FY 2024)Full year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 276% from FY 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Board Change • Aug 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 24No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Dec 05Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,269,231 Price\Range: AUD 0.26 Discount Per Security: AUD 0.0156 Transaction Features: Subsequent Direct Listing
Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.002 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.3m (up 17% from FY 2023). Net loss: AU$338.0k (loss narrowed 95% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.2m (up 17% from FY 2023). Net loss: AU$499.0k (loss narrowed 92% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (AU$65.3m market cap, or US$44.1m).
Board Change • Dec 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 30No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Rod North was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 02Full year 2023 earnings released: AU$0.035 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.035 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 11% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
공시 • Sep 28Compumedics Limited, Annual General Meeting, Oct 31, 2023Compumedics Limited, Annual General Meeting, Oct 31, 2023, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street, Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the Company and the reports of the Directors and the Company's auditor for the year ended 30 June 2023; to consider the election of Director; and to consider the adoption of Remuneration Report.
New Risk • Aug 31New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 43% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (AU$35.4m market cap, or US$23.0m).
공시 • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.
공시 • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.
Reported Earnings • Mar 03First half 2023 earnings released: AU$0.041 loss per share (vs AU$0.002 profit in 1H 2022)First half 2023 results: AU$0.041 loss per share (down from AU$0.002 profit in 1H 2022). Revenue: AU$19.2m (up 14% from 1H 2022). Net loss: AU$7.21m (down AU$7.50m from profit in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings.
공시 • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.
Board Change • Jan 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 29No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 28% per year, which means it is performing significantly worse than earnings.
Board Change • Aug 04No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jul 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Mar 03First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: EPS: AU$0.002 (down from AU$0.007 in 1H 2021). Revenue: AU$16.8m (down 7.0% from 1H 2021). Net income: AU$287.0k (down 78% from 1H 2021). Profit margin: 1.7% (down from 7.3% in 1H 2021). Revenue missed analyst estimates by 4.4%. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Board Change • Jan 28Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Tucson Dunn was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 31Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Independent Non-Executive Director Tucson Dunn was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 01Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$35.7m (up 1.9% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.8% (up from net loss in FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 28Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$37.3m (up 6.2% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.7% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Mar 10New 90-day low: AU$0.41The company is down 17% from its price of AU$0.49 on 08 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period.
Is New 90 Day High Low • Jan 13New 90-day low: AU$0.41The company is down 7.0% from its price of AU$0.45 on 16 October 2020. The Australian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$1.73 per share.